Paradigm Biopharmaceuticals Ltd has released a press release.
Type D Response Submitted and Received by the US FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Half Yearly Report and Accounts
- Primary Endpoint Achieved in Phase 2 MPS VI Trial
- Paradigm Receives $7.36m R&D Tax Incentive Refund
- Security Class Reinstatement to Quotation PARO
- Successful completion of Retail Entitlement Offer
Later from Paradigm Biopharmaceuticals
- Appendix 4E and 2024 Annual Report
- PAR receives positive response from US FDA for phase 3
- Paradigm Investor Update
- Phase 3 Protocol Submission to US FDA
- 2024 Chairman Address and AGM Presentation
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals